(function(){
			var content_array=["<p><strong><em>About Advanced Emphysema <\/em><\/strong><br \/> More than 15 million people worldwide suffer from advanced emphysema, a chronic, debilitating disease most commonly brought on by years of smoking. Emphysema causes irreversible damage to delicate lung tissue, leading to shortness of breath and even feelings of suffocation that result in reduced quality of life. Emphysema is medically characterized by reduced lung function, increased lung volume and loss of the lung's natural elastic properties, which makes breathing very difficult.<\/p>\r\n<p>Emphysema is medically characterized by reduced lung function and increased lung volume, which makes breathing very difficult. As the disease progresses and the lung's natural elastic properties are destroyed, excess air is trapped in the lungs, making it difficult for the person to exhale. This process is known as hyperinflation and is responsible for the feeling of being \"short of breath.\" &nbsp;&nbsp;The RePneu LVRC works by compressing the hyperinflated lung tissue to reduce volume, while helping to restore the lung's natural elastic recoil. The LVRC also helps hold open the lung's airways, preventing airway collapse that causes air trapping and hyperinflation.&nbsp; Implanting the LVRC involves a minimally invasive, non-surgical procedure, and most patients are able to return home the following day.<\/p>\r\n<p>As the disease progresses and lung tissue is destroyed, excess air is trapped in the lungs making it difficult for the person to exhale. This process is known as hyperinflation and responsible for the feeling of being \"short of breath.\"&nbsp; Patients with severe emphysema experience shortness of breath nearly all the time, even when resting, and suffer from continuous fatigue, chronic coughing, wheezing and frequent respiratory infections.&nbsp; Patients are also at higher risk for lung infection, inflammation and other respiratory conditions, as well as serious other systemic conditions such as diabetes[1] &nbsp;and heart disease.[2]&nbsp;<\/p>\r\n<p>As there is no cure for emphysema, the goal of current treatment methods such as drug therapy (inhaled steroids, bronchodilators and antibiotics), supplemental oxygen, and pulmonary rehabilitation (breathing exercises) is to relieve symptoms and teach people how to live with the disease.&nbsp; Eventually, the disease will exhaust these treatment methods, leaving the patient with very few options for symptom relief.[3]<\/p>\r\n<p><strong><em>About PneumRx Inc.<\/em><\/strong><br \/> PneumRx, Inc. is a Mountain View, CA based medical device start-up focused on developing minimally-invasive solutions for unmet medical needs in pulmonary medicine.&nbsp; &nbsp;The flagship product, the RePneu&reg; Lung Volume Reduction Coil, is designed to reduce lung volume and restore elastic recoil to improve lung function, exercise capacity, and quality of life for patients with emphysema.&nbsp; Made from shape-memory Nitinol, the RePneu Coil is designed to compress hyperinflated tissue and tether small airways to prevent airway collapse without blocking airways or inducing fibrosis.&nbsp;&nbsp; The RePneu LVRC is limited to investigational use in the U.S.A.&nbsp; Read more at <a rel=\"nofollow\" href=\"http:\/\/www.pneumrx.com\/\" target=\"_blank\">www.pneumrx.com<\/a>.<\/p>\r\n<p>[1] Emma H Baker MD and Derek Bell MD.&nbsp;<em>Blood glucose: of emerging importance in&nbsp;COPD exacerbations.<\/em>&nbsp;Thorax 2009;64:830-832.<\/p>\r\n<p>[2] Kaiser Permanente Medical Care Program. COPD and Incident Cardiovascular Disease Hospitalizations and Mortality. Chest 2005: 128: 2068-075<\/p>\r\n<p>[3] Centers for Disease Control and Prevention. Chronic Obstructive Pulmonary Disease Surveillance &ndash; United States, 1971-2000. Morbidity and Mortality Weekly Report. August 2, 2002; 51(SS06):1-16.<\/p>\r\n"];
			$("#dvExtra").html(content_array[0]);})();